Achillion Pharmaceuticals, Inc.ACHN was a big mover last session, as the company saw its shares rise more than 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 20.9% in the past one-month time frame.
The move came after Achillion Pharmaceuticals announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion on ACH-4471 for orphan status in the European Union for the treatment of C3 glomerulopathy (C3G).
The company has seen a flat track record when it comes to estimate revisions over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Achillion Pharmaceuticals, Inc. Price
Achillion Pharmaceuticals, Inc. Price | Achillion Pharmaceuticals, Inc. Quote
Achillion Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
A better-ranked stock in the Medical sector is Bioverativ Inc. BIVV, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ACHN going up? Or down? Predict to see what others think: Up or Down
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2018 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment